Celyad Oncology Statistics

Total Valuation

Celyad Oncology has a market cap or net worth of EUR 9.53 million. The enterprise value is 9.58 million.

Market Cap	9.53M
Enterprise Value	9.58M

Important Dates

The next estimated earnings date is Thursday, September 24, 2026.

Earnings Date	Sep 24, 2026
Ex-Dividend Date	n/a

Share Statistics

Celyad Oncology has 44.76 million shares outstanding. The number of shares has increased by 17.90% in one year.

Current Share Class	44.76M
Shares Outstanding	44.76M
Shares Change (YoY)	+17.90%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.48%
Owned by Institutions (%)	0.05%
Float	17.48M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	51.26
PB Ratio	-3.07
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.48
EV / Sales	51.48
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.66

Current Ratio	0.66
Quick Ratio	0.42
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-64.40

Financial Efficiency

Return on equity (ROE) is -7,871.95% and return on invested capital (ROIC) is -405.75%.

Return on Equity (ROE)	-7,871.95%
Return on Assets (ROA)	-43.41%
Return on Invested Capital (ROIC)	-405.75%
Return on Capital Employed (ROCE)	-325.42%
Revenue Per Employee	10,333
Profits Per Employee	-358,611
Employee Count	19
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.03% in the last 52 weeks. The beta is 1.00, so Celyad Oncology's price volatility has been similar to the market average.

Beta (5Y)	1.00
52-Week Price Change	-16.03%
50-Day Moving Average	0.30
200-Day Moving Average	0.42
Relative Strength Index (RSI)	32.39
Average Volume (20 Days)	51,342

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Celyad Oncology had revenue of EUR 186,000 and -6.46 million in losses. Loss per share was -0.16.

Revenue	186,000
Gross Profit	175,000
Operating Income	-6.44M
Pretax Income	-6.46M
Net Income	-6.46M
EBITDA	-6.28M
EBIT	-6.44M
Loss Per Share	-0.16

Full Income Statement

Balance Sheet

The company has 790,000 in cash and 831,000 in debt, giving a net cash position of -41,000 or -0.00 per share.

Cash & Cash Equivalents	790,000
Total Debt	831,000
Net Cash	-41,000
Net Cash Per Share	-0.00
Equity (Book Value)	-3.10M
Book Value Per Share	-0.07
Working Capital	-1.26M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-6.12M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	94.09%
Operating Margin	-3,462.37%
Pretax Margin	-3,470.43%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Celyad Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.90%
Shareholder Yield	-17.90%
Earnings Yield	-67.70%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Celyad Oncology has an Altman Z-Score of -93.11 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-93.11
Piotroski F-Score	3